Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Teva's DEGEVMA Biosimilar to Xgeva for Cancer Bone Complications

29 September 2026 · By · Wire by Fusion42

Published

29 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 29 September 2026 · Fusion42 review

The FDA approved Teva's DEGEVMA as a biosimilar to Xgeva for treating cancer bone complications, marking Teva's entry into this biosimilar market following Sandoz.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 29 Sep 2026 and 30 Sep 2026.

◆ ◆ The Wire takeaway

Teva's FDA nod opens a direct pathway to compete in the lucrative biosimilar space for cancer bone conditions. You need to assess how this shifts supplier and competitive dynamics in oncology biologics now.

◆ Coverage

2 sources · first reported 29 Sep 2026 · latest 30 Sep 2026

◆ Related on Wire

◆ Topics

BiotechbiosimilarFDA-approvalcancer-treatmentbone-complicationsTeva